ATR, a core DDR kinase, senses replication stress and signals S and G2/M checkpoints to initiate DNA repair. It's a hot target in anti-cancer drug development, with some ATR inhibitors already in clinical trials.

This article summarized the latest R&D progress of Pentostatin, the mechanism of action for Pentostatin, and the drug target R&D trends for Pentostatin.

Recently the clinical trial of Nivolumab, a PD-1 blockade, for the treatment of RR HL was reported at the ASCO Congress.

At the 2023 Society for Immunotherapy of Cancer meeting, TILT Biotherapeutics revealed Phase I results for its solo TILT-123 treatment. The firm, a pioneer in cancer immunotherapies, uses this oncolytic virus to activate T-cells, targeting patients with progressive solid tumors.

Aromatase converts androstenedione to estrogens. In postmenopausal women, it mainly comes from adrenal glands. Aromatase inhibitors target high-risk groups, combined with OFS for endocrine therapy.

This article summarized the latest R&D progress of Nicorandil, the mechanism of action for Nicorandil, and the drug target R&D trends for Nicorandil.

On December 11, 2023, This ongoing phase 1, 3+3 dose-escalation/expansion study (NCT04279847) to evaluate the safety and tolerability of INCB057643 will be reported at the ASH Congress.

On October 26th, 2023, KangaBio announced that the FDA has formally approved their clinical trial application for the independently developed KGX101, a fusion protein recombined with IL-12 Fc for intravenous injection. Clinical trials will be held simultaneously in Australia and the US.

The Androgen Receptor (AR) regulates prostate homeostasis and cancer cell survival. AR-targeted therapy boosts survival rates in advanced prostate cancer patients ineffectively cured by surgery or radiation.

This article summarized the latest R&D progress of Nitisinone, the Mechanism of Action for Nitisinone, and the drug target R&D trends for Nitisinone.

The latest research trial study of CBP-501 for the treatment of metastatic PDAC reported at the ESMO Congress exhibits promising therapeutic benefits.

Sensei Biotherapeutics, Inc. revealed initial results from its Phase 1/2 trial's sole therapy dose-increase part for SNS-101, a selectively active human antibody targeting the VISTA immune checkpoint.